Literature DB >> 28226265

Alterations of ubiquitin related proteins in the pathology and development of schizophrenia: Evidence from human and animal studies.

Jessica L Andrews1, Frederic J Goodfellow2, Natalie Matosin3, Mollie K Snelling4, Kelly A Newell5, Xu-Feng Huang6, Francesca Fernandez-Enright7.   

Abstract

Gene expression analyses in post-mortem schizophrenia brains suggest that a number of ubiquitin proteasome system (UPS) genes are associated with schizophrenia; however the status of UPS proteins in the schizophrenia brain is largely unknown. Ubiquitin related proteins are inherently involved in memory, neuronal survival and morphology, which are processes implicated in neurodevelopmental disorders such as schizophrenia. We examined levels of five UPS proteins (Protein Inhibitor of Activated STAT2 [PIAS2], F-Box and Leucine rich repeat protein 21 [FBXL21], Mouse Double Minute 2 homolog [MDM2], Ubiquitin Carboxyl-Terminal Hydrolase-L1 [UCHL1] and Ubiquitin Conjugating Enzyme E2D1 [UBE2D1]) involved in these neuronal processes, within the dorsolateral prefrontal cortex of post-mortem schizophrenia subjects and matched controls (n = 30/group), in addition to across neurodevelopmental time-points (juvenile, adolescent and adult stages of life), utilizing a well-established neurodevelopmental phencyclidine (PCP) animal model of schizophrenia. We observed significant reductions in PIAS2, FBXL21 and MDM2 in schizophrenia subjects compared to controls (p-values ranging from 0.002 to 0.004). In our developmental PCP model, MDM2 protein was significantly reduced in adult PCP-treated rats compared to controls (p = 0.034). Additionally, FBXL21 (p = 0.022) and UCHL1 (p = 0.022) were significantly decreased, whilst UBE2D1 was increased (p = 0.022), in juvenile phencyclidine-treated rats compared to controls. This is the first study reporting alterations of UPS proteins in post-mortem human schizophrenia subjects and in a neurodevelopmental model of schizophrenia. The findings from this study provide strong support for a role of these UPS proteins in the pathology and development of schizophrenia.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  E2 ubiquitin conjugating enzyme; E3 ligases; Human brain cohort; Neurodevelopmental animal model; Schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28226265     DOI: 10.1016/j.jpsychires.2017.01.009

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  5 in total

1.  Ubiquitin-proteasome system, lipid metabolism and DNA damage repair are triggered by antipsychotic medication in human oligodendrocytes: implications in schizophrenia.

Authors:  Gabriela Seabra; Valéria de Almeida; Guilherme Reis-de-Oliveira; Fernanda Crunfli; André Saraiva Leão Marcelo Antunes; Daniel Martins-de-Souza
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

2.  Rps27a might act as a controller of microglia activation in triggering neurodegenerative diseases.

Authors:  Nasibeh Khayer; Mehdi Mirzaie; Sayed-Amir Marashi; Maryam Jalessi
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

3.  Elevated ubiquitinated proteins in brain and blood of individuals with schizophrenia.

Authors:  Chad A Bousman; Sandra Luza; Serafino G Mancuso; Dali Kang; Carlos M Opazo; Md Shaki Mostaid; Vanessa Cropley; Patrick McGorry; Cynthia Shannon Weickert; Christos Pantelis; Ashley I Bush; Ian P Everall
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

4.  Intracellular compartment-specific proteasome dysfunction in postmortem cortex in schizophrenia subjects.

Authors:  Madeline R Scott; James H Meador-Woodruff
Journal:  Mol Psychiatry       Date:  2019-01-25       Impact factor: 15.992

5.  Association between polymorphism of the NEDD4 gene and cognitive dysfunction of schizophrenia patients in Chinese Han population.

Authors:  Chao Han; Kaiyan Cui; Xiaojiao Bi; Lina Wang; Mengmeng Sun; Limin Yang; Lanfen Liu
Journal:  BMC Psychiatry       Date:  2019-12-18       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.